Using ctDNA to Guide Clinical Decision Making in Phase I Oncology Trials

Time: 2:30 pm
day: Day Two


  • ctDNA can be more useful than tumor tissue in identification or screening patients
  • ctDNA can be a PD biomarker as well early indicator of clinical efficacy
  • Longitudinal monitoring emerging tumor gene alterations in ctDNA can help understand resistance mechanisms and guide patient management